BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
54.92
-0.11 (-0.20%)
At close: Oct 17, 2025, 4:00 PM EDT
55.00
+0.08 (0.15%)
After-hours: Oct 17, 2025, 6:29 PM EDT
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $110.57M in the quarter ending June 30, 2025, with 4,999.86% growth. This brings the company's revenue in the last twelve months to $235.81M, up 7.62% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$235.81M
Revenue Growth
+7.62%
P/S Ratio
44.17
Revenue / Employee
$323,030
Employees
730
Market Cap
10.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BBIO News
- 14 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM - GlobeNewsWire
- 25 days ago - BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 - GlobeNewsWire
- 5 weeks ago - BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript) - Seeking Alpha
- 5 weeks ago - BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism - GlobeNewsWire
- 6 weeks ago - BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - GlobeNewsWire
- 6 weeks ago - BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism - GlobeNewsWire